Loading
A phase 2 trial of Tislelizumab and Docetaxel in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07669415 by LaNova Medicines Limited, with 108 participants planned, started 2026-07-29 and due to reach its primary completion in 2027-12-15. Interventions recorded: LM-168, Tislelizumab and Docetaxel injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/